Setrobuvir clinical trials
Also written ANA598.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How each study uses setrobuvir is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2012 (3)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses setrobuvir is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV InfectionCompletedPhase 2Hoffmann-La RocheNCT00978497Written as ANA598
- ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based TreatmentCompletedPhase 2Hoffmann-La RocheNCT01628094Written as RO5466731
- A Relative Bioavailability Study of Setrobuvir Tablet Formulation Versus Reference Setrobuvir Capsule Formulation in Healthy VolunteersCompletedPhase 1Hoffmann-La RocheNCT01612143Written as setrobuvir
- A Study of Setrobuvir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Genotype 1 Chronic Hepatitis CCompletedPhase 2Hoffmann-La RocheNCT01903954Written as setrobuvir
- A Safety And Pharmacokinetic Study of Setrobuvir Alone and In Combination With Ritonavir-Boosted Danoprevir in Subjects With Mild Hepatic Impairment Compared to Healthy ControlsCompletedPhase 1Hoffmann-La RocheNCT01714154Written as setrobuvir
Codes
What other systems call setrobuvir · ClinicalTrials.gg INT000110
- MeSH (NLM) C000592794setrobuvirOne source NLM
- UNII (FDA) T5B2GI8F84SETROBUVIRConfirmed FDA, NLM, Wikidata
- Wikidata Q7456835setrobuvirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152351SetrobuvirOne source FDA
- DrugBank DB12051One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000592794 | setrobuvir | One source NLM |
| UNII (FDA) | T5B2GI8F84 | SETROBUVIR | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7456835 | setrobuvir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152351 | Setrobuvir | One source FDA |
| DrugBank | DB12051 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.